Form 8-K - Current report:
SEC Accession No. 0001104659-24-002059
Filing Date
2024-01-08
Accepted
2024-01-08 07:05:49
Documents
14
Period of Report
2024-01-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm242340d1_8k.htm   iXBRL 8-K 41400
2 EXHIBIT 99.1 tm242340d1_ex99-1.htm EX-99.1 19126
6 GRAPHIC tm242340d1_ex99-1img01.jpg GRAPHIC 8962
  Complete submission text file 0001104659-24-002059.txt   258952

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA immu-20240105.xsd EX-101.SCH 3015
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE immu-20240105_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE immu-20240105_pre.xml EX-101.PRE 22359
8 EXTRACTED XBRL INSTANCE DOCUMENT tm242340d1_8k_htm.xml XML 3312
Mailing Address 665 STOCKTON DRIVE SUITE 300 EXTON PA 19341
Business Address 665 STOCKTON DRIVE SUITE 300 EXTON PA 19341 610-321-3700
Immunome Inc. (Filer) CIK: 0001472012 (see all company filings)

EIN.: 770694340 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39580 | Film No.: 24518295
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)